ANSWER: C

Rationale:

Management of a supratherapeutic INR requires matching the intervention intensity to the severity of bleeding. This patient has minor bleeding (epistaxis requiring packing but no hemodynamic compromise, no transfusion requirement, no evidence of major or life-threatening hemorrhage). For supratherapeutic INR with minor bleeding, current American College of Chest Physicians (ACCP) and American Society of Hematology (ASH) guidelines recommend holding warfarin and administering low-dose oral vitamin K (1 to 2.5 mg) to facilitate INR reduction over 24 hours. Oral vitamin K at this dose reliably lowers the INR without fully reversing anticoagulation — preserving some protection against cardioembolic stroke while bringing the INR toward a safer range. The goal is not immediate full reversal but controlled reduction. Over-reversal (INR below therapeutic range) leaves this patient with AF at significant stroke risk. Four-factor PCC is indicated for life-threatening or major hemorrhage (intracranial bleeding, hemodynamically significant GI bleeding, retroperitoneal bleeding, or bleeding requiring emergency surgery) because it achieves near-immediate factor replacement and INR correction within 15 to 30 minutes — a speed advantage that is clinically critical for intracranial hemorrhage but unnecessary for controlled epistaxis.

• Option A: Option A is incorrect because 4-factor PCC is reserved for life-threatening or major hemorrhage; using it for minor bleeding with a supratherapeutic INR is disproportionate, exposes the patient to unnecessary thrombotic risk from rapid and complete reversal of anticoagulation, and is not guideline-supported for this clinical scenario.
• Option B: Option B is incorrect because FFP is not the preferred reversal agent even for major hemorrhage in warfarin-treated patients — it has been largely superseded by 4-factor PCC due to PCC's superior speed, smaller infusion volume, and more predictable INR correction; furthermore, FFP alone without vitamin K provides only temporary factor replacement with no sustained effect, and it is not indicated for minor bleeding at any dose.
• Option D: Option D is incorrect because simply holding warfarin without administering vitamin K is appropriate only for a supratherapeutic INR without any bleeding — the presence of even minor bleeding in this patient warrants low-dose oral vitamin K to accelerate INR reduction; additionally, vitamin K at doses of 1 to 2.5 mg does not cause prolonged warfarin resistance, which is a concern primarily with high intravenous doses (10 mg).
• Option E: Option E is incorrect because subcutaneous vitamin K is specifically not recommended for warfarin reversal; subcutaneous absorption is erratic, slower, and less predictable than oral absorption, and current guidelines explicitly favor the oral route for non-urgent reversal — intravenous vitamin K is reserved for urgent but not life-threatening reversal situations where oral administration is not feasible.

ANSWER: A

Rationale:

LMWH is the established anticoagulant of choice for VTE treatment and prevention throughout pregnancy. The key pharmacological property enabling its safe use is failure to cross the placenta: LMWH molecules (mean molecular weight approximately 4,500 Da) are too large and too negatively charged to cross the placental barrier via the mechanisms available to small lipophilic molecules, protecting the fetus from direct anticoagulant exposure. This has been confirmed in multiple studies demonstrating undetectable anti-Xa activity in cord blood of LMWH-treated mothers. Warfarin is teratogenic in the first trimester (weeks 6–12), causing warfarin embryopathy characterized by nasal hypoplasia and stippled epiphyses (chondrodysplasia punctata) due to inhibition of vitamin K-dependent carboxylation of matrix Gla protein, which is required for normal bone and cartilage development. Throughout any trimester, warfarin crosses the placenta freely (it is a small, lipophilic molecule) and can cause fetal intracranial hemorrhage, as the fetal coagulation system cannot compensate. DOACs — rivaroxaban, apixaban, edoxaban, dabigatran — are all contraindicated in pregnancy; animal studies demonstrate placental transfer and fetal harm at therapeutic exposures, and there are no adequate human data supporting their safety. LMWH is typically held 12 to 24 hours before planned delivery and bridged with UFH if needed, given UFH's complete protamine reversibility.

• Option B: Option B is incorrect because rivaroxaban is not safe in pregnancy; high protein binding does not prevent placental transfer of the free fraction, DOACs do not carry a blanket Category B designation (they are classified as Category C or have insufficient data), and convenience of dosing does not override teratogenicity and fetal safety concerns.
• Option C: Option C is incorrect because warfarin is not safe after the first trimester; while the embryopathy risk is concentrated in weeks 6 to 12, warfarin crosses the placenta throughout pregnancy as a small lipophilic molecule and can cause fetal intracranial hemorrhage, placental hemorrhage, and neonatal bleeding at any gestational age — it is contraindicated throughout all trimesters.
• Option D: Option D is incorrect because continuous intravenous UFH is not preferred over LMWH for outpatient VTE treatment in pregnancy; LMWH has superior bioavailability, predictable pharmacokinetics, lower rates of heparin-induced thrombocytopenia (HIT), and equivalent or superior efficacy; UFH infusion requires hospitalization and is reserved for situations where rapid reversibility is immediately needed (imminent delivery or surgery), not as the standard long-term treatment approach.
• Option E: Option E is incorrect because fondaparinux is not the preferred agent in pregnancy; while small studies suggest fondaparinux does not substantially cross the placenta, the evidence base is far more limited than for LMWH, and fondaparinux is considered an off-label alternative reserved for patients with LMWH allergy or intolerance — LMWH remains the guideline-supported first choice throughout pregnancy.

ANSWER: E

Rationale:

Cancer-associated thrombosis represents one of the most clinically challenging anticoagulation scenarios because malignancy dramatically increases both thrombotic risk (tissue factor overexpression, tumor-derived microparticles, chemotherapy-induced endothelial injury) and bleeding risk (tumor vascularity, thrombocytopenia from chemotherapy, mucosal fragility). The CLOT trial established dalteparin (LMWH) as superior to warfarin for VTE recurrence prevention in cancer patients, reducing recurrence by approximately 50% compared to warfarin without increasing major bleeding — establishing LMWH as the first evidence-based standard for CAT. The subsequent HOKUSAI-VTE Cancer trial (edoxaban vs dalteparin) and SELECT-D trial (rivaroxaban vs dalteparin) demonstrated that DOACs are non-inferior or superior to LMWH for recurrent VTE prevention in cancer patients, with the important finding that both edoxaban and rivaroxaban were associated with significantly higher rates of major bleeding in patients with gastrointestinal and genitourinary cancers — particularly luminal GI tumors — compared to LMWH. This bleeding signal in luminal GI malignancies is mechanistically explained by direct drug contact with fragile tumor mucosa in the GI tract, which is not a concern with parenterally administered LMWH. Current guidelines (ASCO, ISTH, NCCAP) recommend LMWH or DOACs for CAT, with the explicit caveat that DOACs should be used with caution or avoided in patients with luminal GI or genitourinary malignancies at high bleeding risk. Given this patient's history of GI bleeding from a colorectal primary — even though currently resected — LMWH is the more appropriate and conservative selection.

• Option A: Option A is incorrect because warfarin is specifically inferior to LMWH in cancer-associated thrombosis as demonstrated by the CLOT trial; cancer patients have highly variable vitamin K intake, frequent drug interactions with chemotherapy agents, and thrombocytopenia that complicates INR management — warfarin is not recommended as a first-line agent for CAT in current guidelines.
• Option B: Option B is incorrect because continuous intravenous UFH is not the preferred approach for long-term outpatient management of cancer-associated thrombosis; UFH requires hospitalization for continuous infusion, carries higher HIT risk than LMWH, and has not demonstrated superiority over LMWH in CAT — it is reserved for acute inpatient management or situations where subcutaneous dosing is not feasible.
• Option C: Option C is incorrect because fondaparinux has not been established as a first-line agent for cancer-associated thrombosis in major randomized controlled trials; while its anti-Xa mechanism is pharmacologically sound, guideline recommendations for CAT are based on LMWH and DOAC trial data, not fondaparinux data.
• Option D: Option D is incorrect because the SELECT-D trial did not demonstrate superior efficacy across all cancer subtypes without increased bleeding; rivaroxaban showed superior efficacy for recurrent VTE prevention but was associated with a clinically significant increase in major bleeding — particularly in patients with upper GI cancers — compared to dalteparin, and the trial did not include sufficient arterial thromboembolic endpoints to support a claim of superiority across all thromboembolic outcomes.

ANSWER: B

Rationale:

The management of patients requiring both antiplatelet therapy (for coronary stent protection) and anticoagulation (for AF stroke prevention) represents a high-stakes balancing act between ischemic and hemorrhagic risk. Traditional triple therapy (aspirin plus a P2Y12 inhibitor plus an oral anticoagulant) substantially increases major bleeding — including intracranial and gastrointestinal hemorrhage — compared to dual or single antithrombotic therapy, without demonstrating a clear reduction in ischemic events over dual therapy in most patients. The AUGUSTUS trial randomized AF patients post-ACS or PCI to apixaban versus warfarin and to aspirin versus placebo (factorial design), demonstrating that apixaban significantly reduced major or clinically relevant non-major bleeding compared to warfarin, and that dropping aspirin (while maintaining P2Y12 inhibition plus anticoagulation) reduced bleeding without increasing stent thrombosis or ischemic stroke. The PIONEER AF-PCI trial similarly demonstrated reduced bleeding with rivaroxaban-based regimens versus warfarin-based triple therapy. Current ACC/AHA and ESC guidelines support DOAC plus P2Y12 inhibitor dual therapy (dropping aspirin after an initial very short period of triple therapy, typically 1 to 4 weeks post-PCI in selected patients) as the preferred strategy to reduce bleeding while maintaining adequate protection against both stent thrombosis and cardioembolic stroke. In this patient — 3 weeks post-DES, with high AF stroke risk — DOAC plus ticagrelor without aspirin is the guideline-concordant approach.

• Option A: Option A is incorrect because warfarin-based triple therapy has been demonstrated in multiple randomized trials (AUGUSTUS, PIONEER AF-PCI, ENTRUST-AF PCI) to produce significantly higher rates of major bleeding than DOAC-based dual therapy without a compensatory reduction in ischemic events; current guidelines specifically recommend DOACs over warfarin and dual over triple therapy in most AF patients post-PCI.
• Option C: Option C is incorrect because DOAC anticoagulation alone does not provide adequate protection against coronary stent thrombosis; stent thrombosis is driven by platelet activation at the thrombogenic metal surface, which requires dedicated antiplatelet therapy targeting platelet activation pathways (COX-1 via aspirin and P2Y12 via ticagrelor/clopidogrel) — factor Xa inhibition does not adequately suppress platelet-mediated stent thrombosis.
• Option D: Option D is incorrect because 12 months of triple therapy is not mandated for all DES patients requiring anticoagulation; the default DAPT duration after DES can be shortened in patients at high bleeding risk — particularly those requiring concurrent anticoagulation — to as little as 1 month of triple therapy followed by transition to dual therapy, based on individualized ischemic versus bleeding risk assessment using tools such as the PRECISE-DAPT score.
• Option E: Option E is incorrect because ticagrelor's reversible P2Y12 inhibition is not inferior to clopidogrel for stent protection — ticagrelor provides more potent and consistent P2Y12 inhibition than clopidogrel (which requires CYP2C19 activation and has variable response due to pharmacogenomic variation); furthermore, warfarin is not superior to DOACs for AF stroke prevention in patients with recent ACS, and DOAC-based dual therapy is the preferred contemporary approach.

ANSWER: D

Rationale:

This presentation is classic for heparin-induced thrombocytopenia type II (HIT): thrombocytopenia beginning on day 5 to 14 of heparin exposure (here day 9), a greater than 50% platelet count fall, and new arterial thrombosis (stroke) in a patient on UFH — yielding a 4T score of 7, consistent with high clinical probability. HIT is an immune-mediated prothrombotic disorder, not simply a bleeding disorder, and its management is counterintuitive: despite severe thrombocytopenia, the primary risk is thrombosis (not hemorrhage), and platelet transfusion is specifically contraindicated unless life-threatening bleeding is present — transfused platelets carry FcγRIIa receptors and are activated by circulating HIT antibodies, potentially precipitating further thrombosis (the "platelet transfusion fuels the fire" principle). All heparin must be stopped immediately and completely — including heparin flushes, LMWH (which cross-reacts with HIT antibodies in approximately 85–90% of cases), and heparin-coated devices where feasible. A non-heparin anticoagulant must be started immediately at therapeutic doses, even in the presence of thrombocytopenia, because ongoing thrombin generation is the life-threatening process. Argatroban is the agent of choice in this patient (normal hepatic function assumed; renal function not specified but argatroban is hepatically cleared and safe in renal impairment). Bivalirudin is an acceptable alternative. The concurrent acute ischemic stroke in the context of HIT represents an extreme management challenge — systemic thrombolysis is generally contraindicated with concurrent thrombocytopenia and HIT, requiring urgent multidisciplinary input.

• Option A: Option A is incorrect because continuing or increasing UFH in confirmed or high-probability HIT directly perpetuates the immune-mediated platelet activation driving both the thrombocytopenia and the thrombosis — this is the most dangerous possible response to HIT and would be expected to accelerate the prothrombotic process.
• Option B: Option B is incorrect because LMWH cross-reacts with HIT antibodies in approximately 85 to 90% of cases; the HIT antibody recognizes the heparin-PF4 neoantigen, and LMWH — despite its shorter chain length — binds PF4 sufficiently to form immunogenic complexes that are recognized by the same IgG antibodies; substituting LMWH for UFH in HIT is specifically contraindicated in all current guidelines.
• Option C: Option C is incorrect because platelet transfusion in HIT is specifically contraindicated in the absence of life-threatening hemorrhage; in HIT, platelets are consumed because they are being activated and aggregated by HIT antibodies — transfusing more platelets provides additional substrate for FcγRIIa-mediated activation and risks precipitating further arterial or venous thrombosis; the thrombocytopenia of HIT resolves with cessation of heparin and establishment of alternative anticoagulation, not with platelet transfusion.
• Option E: Option E is incorrect because fondaparinux does not have a formal FDA indication for HIT treatment; while fondaparinux is used off-label in some HIT patients (particularly for outpatient transition therapy) based on case series and small studies showing it does not cross-react with most HIT antibodies, it is not a first-line guideline-recommended agent for acute HIT with active thrombosis — argatroban and bivalirudin are the FDA-approved and guideline-endorsed agents for this indication.

ANSWER: A

Rationale:

The four approved DOACs differ substantially in their dependence on renal elimination, and this difference is the primary pharmacokinetic criterion for DOAC selection in patients with reduced GFR. Dabigatran (a direct thrombin inhibitor) is approximately 80% renally eliminated and is contraindicated when eGFR falls below 30 mL/min/1.73 m² (15 mL/min/1.73 m² per European labeling) — in this patient with eGFR 32, dabigatran is at the margin of its safe use range and should be avoided. Edoxaban (direct FXa inhibitor) is approximately 50% renally cleared and requires dose reduction to 30 mg daily when eGFR is 15–50 mL/min/1.73 m². Rivaroxaban (direct FXa inhibitor) is approximately 33% renally eliminated and requires dose reduction (15 mg once daily with evening meal) when eGFR is 15–49 mL/min/1.73 m². Apixaban (direct FXa inhibitor) has the lowest renal dependence at approximately 27%, with the remainder cleared via hepatic metabolism and biliary/fecal excretion; it maintains predictable pharmacokinetics across a wide range of renal function. Apixaban's dose-reduction criteria (reduce from 5 mg to 2.5 mg twice daily if two of three criteria are met: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL) apply here based on age and creatinine — this patient meets two criteria and should receive apixaban 2.5 mg twice daily. Apixaban has the strongest evidence base and pharmacokinetic rationale for use in moderate-to-severe CKD among the DOACs.

• Option B: Option B is incorrect because dabigatran's high renal elimination is a liability, not an advantage, in CKD — accumulation leads to supratherapeutic plasma concentrations and increased bleeding risk, not therapeutic benefit in the renal tubular system; AF-related cardioembolic stroke arises from thrombus in the left atrial appendage, not the renal tubules.
• Option C: Option C is incorrect because rivaroxaban does require dose adjustment in renal impairment — it is reduced to 15 mg once daily when eGFR is 15–49 mL/min/1.73 m²; the claim that it has no GFR-dependent pharmacokinetics is incorrect, as approximately 33% of rivaroxaban is renally eliminated and plasma concentrations increase meaningfully with declining GFR.
• Option D: Option D is incorrect because the dose-reduction algorithms for different DOACs are not interchangeable and do not produce equivalent safety profiles across all renal impairment stages — dabigatran's high renal dependence makes it substantially riskier in moderate-to-severe CKD than apixaban regardless of dose adjustment, and the pharmacokinetic differences between agents are clinically meaningful when selecting treatment for an individual patient.
• Option E: Option E is incorrect because DOACs are not nephrotoxic — there is no established mechanism by which DOACs cause direct tubular injury or accelerate CKD progression; in fact, accumulating evidence suggests DOACs (particularly apixaban) may have a more favorable renal safety profile than warfarin in CKD, where warfarin-associated nephropathy (glomerular hemorrhage and tubular red cell cast formation from anticoagulant-related microhematuria) is a recognized complication.

ANSWER: C

Rationale:

Rivaroxaban's pharmacokinetics are significantly influenced by renal function. In patients with normal renal function, rivaroxaban has a half-life of approximately 5 to 9 hours; in moderate renal impairment (eGFR 30–49 mL/min/1.73 m²), half-life extends to approximately 9 to 13 hours due to reduced renal clearance of the drug and its metabolites. At 18 hours after the last dose in a patient with eGFR 48, substantial residual anti-Xa activity is plausible — simple time elapsed cannot be used to confidently declare the patient anticoagulant-free. The appropriate approach for truly urgent surgery is to measure residual rivaroxaban activity (anti-Xa level calibrated for rivaroxaban if available, or an anti-Xa activity assay) and if the level indicates clinically significant anticoagulation — or if the assay is unavailable and the surgical bleeding risk is high — administer andexanet alfa. Andexanet alfa is a recombinant modified factor Xa (catalytically inactive) that acts as a decoy substrate, sequestering free rivaroxaban (and apixaban) and rapidly reversing anti-Xa activity. It was approved by the FDA based on the ANNEXA-4 trial (a prospective cohort study demonstrating hemostatic efficacy in patients with major bleeding on FXa inhibitors). For situations where andexanet alfa is unavailable, 4-factor PCC (off-label) is a reasonable alternative based on ex vivo and observational data, though its reversal mechanism (factor replacement rather than drug sequestration) is mechanistically less specific.

• Option A: Option A is incorrect because rivaroxaban's half-life is not 2 to 3 hours — it is 5 to 9 hours in normal renal function and longer in renal impairment; furthermore, even at 5 to 9 hours, 18 hours represents only 2 to 3 half-lives, not 6, meaning approximately 12 to 25% of the drug's anticoagulant effect may remain — a clinically meaningful residual in major surgery.
• Option B: Option B is incorrect because idarucizumab is a specific reversal agent for dabigatran only — it is a monoclonal antibody Fab fragment with approximately 350-fold higher affinity for dabigatran than dabigatran has for thrombin; it has no binding affinity for rivaroxaban or any other direct FXa inhibitor and would have no reversal effect.
• Option D: Option D is incorrect because 4-factor PCC is not the FDA-approved or guideline-preferred first-line reversal agent for direct FXa inhibitors — andexanet alfa holds that role for rivaroxaban and apixaban; 4-factor PCC is an off-label alternative when andexanet alfa is unavailable or not appropriate, and administering it as a first-line agent ahead of andexanet alfa is not consistent with current reversal guidelines.
• Option E: Option E is incorrect because a blanket 48-hour hold policy ignores pharmacokinetic reality (for patients with normal renal function and a short half-life drug, 48 hours is unnecessary; for patients with severe renal impairment, 48 hours may still be insufficient) and because withholding reversal entirely is not appropriate when a specific reversal agent exists and surgery cannot be safely delayed — the risk-benefit assessment for andexanet alfa must be individualized, not categorically refused.

ANSWER: E

Rationale:

This patient presents a textbook case of therapeutic failure in triple-positive APS on rivaroxaban — the exact scenario the TRAPS trial was designed to evaluate. The TRAPS trial randomized patients with high-risk triple-positive APS (the vast majority with prior thrombosis) to rivaroxaban 20 mg once daily or warfarin (target INR 2.0–3.0 for venous thrombosis history, 2.5–3.5 for arterial events). The trial was terminated early after the Data Safety Monitoring Board identified a significant excess of thromboembolic events in the rivaroxaban arm — including multiple strokes and TIAs — compared to warfarin, despite rivaroxaban achieving expected therapeutic plasma levels. The mechanism of warfarin's superiority in APS is not definitively established but likely reflects the broader anticoagulant coverage provided by simultaneous suppression of factors II, VII, IX, and X, which may better counteract the multi-pathway, complement-driven, and tissue factor-mediated thrombin generation characteristic of APS, compared to rivaroxaban's selective FXa inhibition. International guidelines from the European Society of Cardiology, European League Against Rheumatism, and American College of Rheumatology now specifically contraindicate DOACs in triple-positive APS patients with prior thrombosis, recommending warfarin exclusively. This patient's new TIA while on rivaroxaban — occurring in a triple-positive APS patient — is precisely the clinical outcome predicted by and documented in the TRAPS trial.

• Option A: Option A is incorrect because doubling the rivaroxaban dose to 20 mg twice daily is not an approved or guideline-supported strategy for APS management and does not address the fundamental inadequacy of single-target FXa inhibition in the complex thrombotic milieu of triple-positive APS; the TRAPS trial failure occurred at standard therapeutic rivaroxaban concentrations, indicating that dose escalation is unlikely to resolve the mechanistic limitation.
• Option B: Option B is incorrect because apixaban has not been demonstrated to be superior to rivaroxaban in APS in randomized trials; while the ASTRO-APS trial evaluated apixaban in APS (with mixed results), apixaban is not guideline-endorsed for high-risk triple-positive APS with prior arterial thrombosis, and the pharmacokinetic difference between apixaban and rivaroxaban does not translate to a demonstrated clinical outcome advantage in this population.
• Option C: Option C is incorrect because adding aspirin to rivaroxaban has not been validated as an adequate strategy for triple-positive APS with arterial thrombosis; while antiplatelet therapy has a role in some APS manifestations, the TRAPS trial failure with rivaroxaban monotherapy is not resolved by adding aspirin, and current guidelines do not recommend this combination as an alternative to warfarin in high-risk triple-positive APS.
• Option D: Option D is incorrect because indefinite therapeutic LMWH has not been established as superior to warfarin in randomized trials for long-term secondary VTE prevention in APS; LMWH is used in specific situations such as pregnancy-associated APS thrombosis (where warfarin is contraindicated) but is not the recommended long-term oral alternative to warfarin in non-pregnant triple-positive APS patients.

ANSWER: B

Rationale:

Warfarin is administered as a racemic mixture of R- and S-enantiomers. The S-enantiomer is approximately 3 to 5 times more potent as a VKORC1 inhibitor than the R-enantiomer and is responsible for the majority of warfarin's clinical anticoagulant effect. S-warfarin is metabolized almost exclusively by CYP2C9 to its inactive 7-hydroxy metabolite. Fluconazole is one of the most potent clinically available CYP2C9 inhibitors — it inhibits CYP2C9 competitively, reducing S-warfarin clearance and causing S-warfarin plasma concentrations to approximately double or triple with co-administration, depending on fluconazole dose and duration. The resulting increase in VKORC1 inhibition suppresses vitamin K-dependent factor synthesis more completely, causing a substantial and clinically dangerous INR elevation. This interaction is predictable, well-documented, and clinically significant: INR increases of 50 to 100% or more are reported. Management requires empiric warfarin dose reduction (typically 25 to 50%) at the time fluconazole is started, close INR monitoring during the antifungal course, and further INR monitoring after fluconazole discontinuation to prevent under-anticoagulation as CYP2C9 inhibition resolves and S-warfarin clearance normalizes. The R-enantiomer is metabolized primarily by CYP3A4 and CYP1A2 and is relatively unaffected by fluconazole at standard doses.

• Option A: Option A is incorrect because warfarin is not a prodrug requiring CYP3A4 activation — it is pharmacologically active as administered; both enantiomers exert direct VKORC1 inhibitory activity without metabolic activation, and the mechanism of the fluconazole-warfarin interaction is pharmacokinetic inhibition of S-warfarin elimination via CYP2C9, not impairment of prodrug activation.
• Option C: Option C is incorrect because warfarin is not a P-glycoprotein substrate — its high oral bioavailability (approximately 93–100%) is not dependent on P-gp efflux, and P-gp inhibition is not a recognized mechanism of the fluconazole-warfarin interaction; the interaction is entirely mediated by CYP2C9 inhibition affecting hepatic S-warfarin clearance.
• Option D: Option D is incorrect because fluconazole is a CYP2C9 inhibitor, not an inducer — enzyme induction would increase S-warfarin metabolism and lower the INR, the opposite of what is observed; the description of R-warfarin compensatory elevation through enterohepatic recirculation is pharmacologically incoherent and does not reflect established warfarin pharmacokinetics.
• Option E: Option E is incorrect because fluconazole does not inhibit VKORC1 directly; fluconazole is an antifungal that works by inhibiting fungal lanosterol 14-alpha-demethylase (CYP51), a fungal cytochrome P450 enzyme involved in ergosterol synthesis — it has no direct inhibitory effect on the mammalian vitamin K epoxide reductase enzyme and exerts no pharmacodynamic interaction at the warfarin target site.

ANSWER: D

Rationale:

Massive PE — defined by hemodynamic instability (sustained systolic BP <90 mmHg, requirement for vasopressors, or cardiac arrest attributable to PE) — carries an in-hospital mortality of 25 to 65% and represents the primary indication for systemic thrombolysis with alteplase. Alteplase (recombinant tPA) works by binding to fibrin within the thrombus — this fibrin binding localizes alteplase activity to the clot surface, where it converts fibrin-bound plasminogen to plasmin with relative (though not absolute) clot specificity. Plasmin then cleaves fibrin cross-links, degrading the embolus, reducing pulmonary artery pressure and right ventricular afterload, and restoring right ventricular function. The standard regimen is 100 mg intravenous infusion over 2 hours (with UFH held during the infusion and resumed when the aPTT falls below 80 seconds after infusion completion). The hemodynamic emergency of massive PE — right ventricular failure, obstructive shock, impending cardiac arrest — justifies accepting the approximately 1.5 to 2% risk of intracranial hemorrhage associated with systemic thrombolysis, because the untreated condition carries far higher mortality. Anticoagulation alone (UFH) prevents further clot propagation but does not actively lyse existing thrombus rapidly enough to reverse the acute hemodynamic crisis. Absolute contraindications to systemic thrombolysis include prior intracranial hemorrhage, known intracranial structural lesion, ischemic stroke within 3 months, active internal bleeding (excluding menses), significant closed head trauma within 3 months, and intracranial or spinal surgery within 3 months.

• Option A: Option A is incorrect because anticoagulation alone in massive PE with hemodynamic instability carries very high mortality — UFH prevents new thrombus formation and propagation but relies entirely on the endogenous fibrinolytic system for clot dissolution, a process too slow to reverse acute obstructive shock; the intracranial hemorrhage risk of thrombolysis is approximately 1.5 to 2%, not prohibitive when compared to the 25 to 65% mortality of untreated massive PE.
• Option B: Option B is incorrect because the standard alteplase regimen for massive PE is 100 mg over 2 hours, not a 10 mg bolus — the 10 mg dose is used for peripheral arterial thrombolysis in different indications; bolus dosing of alteplase in PE has not demonstrated equivalent efficacy to the standard infusion, and the claim of lower intracranial hemorrhage risk with bolus dosing is not established.
• Option C: Option C is incorrect because streptokinase is not antigen-free — it is derived from streptococcal bacteria and is immunogenic, causing allergic reactions in up to 5% of patients and becoming inactive in patients with prior streptococcal exposure due to neutralizing antibodies; furthermore, streptokinase is not fibrin-specific — it activates circulating (systemic) plasminogen non-selectively, producing a systemic lytic state with higher bleeding risk than alteplase's fibrin-targeted mechanism.
• Option E: Option E is incorrect because the PEITHO trial evaluated tenecteplase versus placebo (plus heparin) in intermediate-high risk submassive PE — not massive PE — and the comparator was anticoagulation alone, not alteplase; PEITHO did not demonstrate a mortality benefit for tenecteplase and showed a significantly increased rate of intracranial hemorrhage; tenecteplase is not guideline-endorsed as preferred over alteplase for massive PE, and its longer half-life is not an advantage in this acute setting.

ANSWER: C

Rationale:

The management of confirmed VTE in thrombocytopenic patients requires explicit risk-benefit weighing rather than a reflexive platelet-threshold-based withholding of anticoagulation. Proximal DVT — particularly in a postoperative cancer patient — carries a meaningful risk of fatal pulmonary embolism: untreated proximal DVT has a PE rate of approximately 40 to 50% without treatment, and PE mortality in cancer patients is substantial. A platelet count of 28 × 10⁹/L increases the risk of major bleeding with therapeutic anticoagulation, but does not make such anticoagulation categorically contraindicated. Current guidance from the American Society of Hematology (ASH) and International Society on Thrombosis and Haemostasis (ISTH) generally supports therapeutic anticoagulation for confirmed proximal VTE even at platelet counts of 25 to 50 × 10⁹/L when thrombotic risk is high, with careful individual risk-benefit assessment. Below approximately 25 × 10⁹/L, the risk-benefit balance shifts further toward withholding anticoagulation or using prophylactic dosing, but even this threshold is not absolute. LMWH is the preferred agent given the cancer-associated VTE context. Platelet transfusion to a target level may be considered to facilitate anticoagulation in extreme cases, but is not a prerequisite before initiating LMWH when the thrombotic risk is immediate. The treating team should involve hematology, oncology, and surgery in a multidisciplinary decision — but doing nothing (withholding anticoagulation entirely for a confirmed proximal DVT) is not a safe default position in this patient.

• Option A: Option A is incorrect because thrombocytopenia at a platelet count of 28 × 10⁹/L is not an absolute contraindication to therapeutic anticoagulation in the setting of confirmed high-risk proximal DVT; compression stockings and elevation are inadequate alternatives for established proximal DVT in a cancer patient at high PE risk, and awaiting platelet recovery introduces unacceptable delay in treatment.
• Option B: Option B is incorrect because systemic thrombolysis is contraindicated rather than preferred in a patient with platelet count of 28 × 10⁹/L and 5-day-old major abdominal surgery — it carries an extremely high hemorrhagic risk in this setting, including surgical site hemorrhage and spontaneous intracranial bleeding; thrombolysis is not an appropriate substitute for anticoagulation in this scenario.
• Option D: Option D is incorrect because platelet transfusion does not enhance heparin-AT-III anticoagulant efficacy; heparin works by binding AT-III in plasma — platelet-derived phospholipid surfaces and factor Va are components of the procoagulant prothrombinase complex, and their presence does not facilitate anticoagulation; the rationale described for platelet transfusion here is pharmacologically inverted.
• Option E: Option E is incorrect because prophylactic-dose fondaparinux has not been validated in randomized controlled trials for the treatment of established proximal DVT in thrombocytopenic patients; sub-therapeutic anticoagulation for confirmed proximal DVT does not adequately prevent PE propagation and is not an evidence-based compromise strategy — the clinical decision should be between full therapeutic anticoagulation (with appropriate monitoring) or, in extreme cases, an inferior vena cava filter as a temporary bridge, not simply halving the dose.